Björn Nashan
[an error occurred while processing this directive]

    Björn Nashan

  • Björn Nashan, MD, PhD, FACS, FRCSC, FEBS

    Professor of Surgery, School of Life Sciences

    University of Science & Technology of China

    443 Huangshan Street, Hefei City, Anhui 230027, P.R.China


    Education and Appointment:

    11/2017present: Professor of Surgery, First Affiliated Hospital, University of Science and Technology of China (USTC)

    07/2007 - 09/2017: Professor of Surgery, Director and Chairman, Department of Hepatobiliary Surgery and Transplantation, Universitäts Klinikum Hamburg-Eppendorf, Hamburg, Germany

    11/2003 - 07/2007: Professor of Surgery, Immunology and Microbiology, Director, Multiorgan Transplant Program, QEII Health Science Centre, DalhousieUniversity, Halifax, Nova Scotia, Canada

    04/1994 10/2003: Consultant - Zentrum Chirurgie, Abteilung für Viszeral- und Transplantationschirurgie, Medizinische Hochschule Hannover, Hannover, Germany

    04/1988 03/1994: Residency - Zentrum Chirurgie, Abteilung für Abdominal- und Transplantationschirurgie, Abteilung für Herz-, Thorax-, und Gefäßchirurgie, Abteilung für Unfallchirurgie, Medizinische Hochschule Hannover, Hannover, Germany

    02/1986 03/1988: Resident Research Fellow - Transplantation immunological Laboratory, Abteilung für Abdominal- und Transplantationschirurgie, Medizinische Hochschule Hannover, Hannover

    Research Field of Interest:

    Transplantation Immunology, Signal Molecules in Tumor Biology, Clinical Trials


    Clinic: Primary and secondary Malignancies in the liver, surgical techniques for liver resection (e.g. ALPPS), Split-Liver Transplantation and Liver Transplantation in Children, Living Liver Donation, 3D CT  reconstruction, laparoscopic und retro- peritoneoscopic Living Kidney Donation Immunosuppression (CNI Minimisation respectively Elimination, personalised Immunosuppression, Development of Immunosuppression in Phase I-III Studies)

    Research: Molecular Oncology (AKT, mTOR pathways)

    Transplantation Immunology (IL-2R, CNI, mTOR and signal 2 pathway;

    Mechanisms of chronic rejection in kidney/liver)

    Selected Publications (25 out of 302):

    1.Nashan B, Schlitt H J, Tusch G, Oldhafer K, Ringe B, Wagner S, Pichlmayr R. Biliarymalignancies in primary sclerosing cholangitis. Timing for liver transplantation.Hepatology 1996. 23:1105-11

    2.Nashan B, Schlitt H J, Schwinzer R, Ringe B, Kuse E, Tusch G, Wonigeit K, Pichlmayr R.Immunoprophylaxis with a monoclonal anti IL-2 receptor antibody in liver transplantedpatients.Transplantation 1996; 61:546-54

    3.Nashan B, Moore R, Amlot P, A G Schmidt, K Abeywickrama, J P Soulillou. Randomisedtrial of basiliximab versus placebo for control of acute cellular rejection in renal allograftrecipients.The Lancet1997; 350:1193-8.

    4.Nashan B, Light S, Hardie IR, Lin A, Johnson R. Reduction of acute renal allograft rejectionby daclizumab. Transplantation 1999; 67:110-5.

    5. Neipp M, G Offner G, R Lück R, Ehrich JHH, Strehlau J, Schlitt H J, Klempnauer J,Nashan B. Kidney transplantation in small children: Donor selection and technical consideration.Transplantation. 2002; 73: 409-16.

    6.Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T on behalf of the 156 StudyGroup. Everolimus in Combination with Reduced-Exposure Cyclosporine in de novo RenalTransplant. Recipients: Results of a 3-Year Phase II, Randomized, Multicenter, Open- Label Study.Transplantation 2004; Nov 15;78(9):1332-40.

    7. Neipp M, Jackobs S, Becjer T, Lueck R, Meyer zu Vilsendorf A, Winny M, Klempnauer J,Nashan B. Living Donor Nephrectomy: Flank Incision vs. Anterior Vertical Mini-Incision. Transplantation2004; 15;78(9):1356-61.

    8. Vincenti F, Larsen C, Durrbach A, Wekerle T,Nashan B, Blancho G, Lan P, Grinyo J, Halloran P F, Solez K, Hagerty D, Levy E, Zhou W, Natarajan K, Charpentier B; BelataceptStudy Group. Costimulation blockade with belatacept in renal transplantation.N Engl JMed. 2005; 353:770-81.

    9. Frericks BB, Kirchhoff TD, Shin H O, Stamm G, Merkesdal S, Abe T, Schenk A, Peitgen HO, Klempnauer J, Galanski M,Nashan B. Preoperative volume calculation of the hepaticvenous draining areas with multi-detector row CT in adult living donor livertransplantation: impact on surgical procedure.Eur Radiol. 2004 Feb;14(2):326-33.

    10. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, Margreiter R, HugoC, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran; ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation.N Engl J Med. 2007Dec 20;357(25):2562-75.

    11.Nashan B, Saliba F, Durand F, Barcéna R, Herrero J I, Mentha G, Neuhaus P, Bowles M, Patch D, Bernardos A, Klempnauer J, Bouw R, Ives, R J Mamelok, D Mc Kay, M Truman, PMarotta. Pharmacokinetics, efficacy, and safety of mycophenolate mofetil incombination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. Liver Transpl. 2009 Feb;15(2):136-47.

    12. Vincenti F, Blancho G, Durrbach A, Friend P, Grinyo J, Halloran P F, Klempnauer J, Lang P, Larsen C P, Mühlbacher F, Nashan B, Soulillou J P, Vanrenterghem Y, Wekerle T, AgarwalM, Gujrathi v, Shen J, R Shi R, Townsend R, Charpentier B. Five-year safety and efficacy ofbelatacept in renal transplantation. J Am Soc Nephrol. 2010. Sep;21(9):1587-96. PMID:20634298

    13. Friman S, Arns W,Nashan B, Vincenti F, Banas B, Budde K, Cibrik D, Chan L, Klempnauer J, Mulgaonkar S, Nicholson M, Wahlberg J, Wissing KM, Abrams K, Witte S, Woodle ES. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase IIstudy in renal transplant recipients.Am J Transplant. 2011 Jul;11(7):1444-55.

    14. Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U,Nashan B, Jücker M. Combined targeting of AKT and mTOR synergistically inhibits proliferation ofhepatocellular carcinoma cells. Mol Cancer. 2012 Nov 20;11:85.

    15. Ewald F, Grabinski N, Grottke A, Windhorst S, Nörz D, Carstensen L, Staufer K, HofmannBT, Diehl F, David K, Schumacher U,Nashan B, Jücker M. Combined targeting of AKT andmTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.Int J Cancer. 2013 Apr 16.

    16. David KA, Unger FT, Uhlig P, Juhl H, Moore HM, Compton C,Nashan B, Dörner A, deWeerth A, Zornig C. Surgical procedures and postsurgical tissue processing significantlyaffect expression of genes and EGFR-pathway proteins in colorectal cancer tissue.Oncotarget. 2014 Nov 30;5(22):11017-28. doi: 10.18632/oncotarget.2669.

    17. Ewald F, Nörz D, Grottke A, Hofmann BT,Nashan B, Jücker, M. Dual Inhibition of PI3K- AKT-mTOR- and RAF-MEK-ERK-signalling is synergistic in cholangiocarcinoma andreverses acquired resistance to MEK-inhibitors.Invest New Drugs. 2014 Dec;32(6):1144- 54. doi: 10.1007/s10637-014-0149-7.

    18. Nörz D, Grottke A, Bach J, Herzberger C, Hofmann BT,Nashan B, Jücker M, Ewald F. Discontinuing MEK inhibitors in tumor cells with an acquired resistance increasesmigration and invasion. Cell Signal. 2015 Jul 22. pii: S0898-6568(15)00213-2. doi:10.1016/j.cellsig.2015.07.016.

    19. Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen LH, Klümpen HJ, Lohse AW,NashanB, Primrose J, Schrum S, Shannon J, Vettorazzi E, Wege H. Adjuvant chemotherapy withgemcitabine and cisplatin compared to observation after curative intent resection ofcholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - arandomized, multidisciplinary, multinational phase III trial.BMC Cancer. 2015 Jul31;15:564. doi: 10.1186/s12885-015-1498-0.

    20. Li J, Kantas A, Ittrich H, Koops A, Achilles E G, Fischer L,Nashan B. Avoid All-Touch byHybrid ALPPS to Achieve Oncological Efficacy. Ann Surg. 2016 Jan;263(1):e6-7. doi:10.1097/SLA.0000000000000845. PMID:25072445

    21.Nashan B, Hugo C, Strassburg CP, Arbogast H, Rahmel A, Lilie H. Transplantation inGermany.Transplantation. 2017 Feb;101(2):213-218. doi:10.1097/TP.0000000000001554

    22. Schütz E, Fischer A, Beck J, Harden M, Koch M, Wuensch T, Stockmann M, Nashan B, Kollmar O, Matthaei J, Kanzow P, Walson PD, Brockmöller J, Oellerich M. Graft-derivedcell-free DNA, a non-invasive early rejection and graft damage marker in livertransplantation: A prospective, observational, multicentre cohort study.PLoS Med. 2017Apr 25;14(4):e1002286. doi: 10.1371/journal.pmed.1002286. eCollection 2017 Apr

    23. Lunemann S, Martrus G, Goebels H, Kautz T, Langeneckert A, Salzberger W, Koch M, JBunders M, Nashan B,van Gisbergen KPJM, Altfeld M. Hobit expression by a subset ofhuman liver-resident CD56bright Natural Killer Cells. Sci Rep. 2017 Jul 27;7(1):6676. doi:10.1038/s41598-017-06011-7.

    24. Herden U, Fischer L, Koch M, Li J, Achilles E,Nashan B. Outcome following right- extended split liver transplantation in the recent transplant era: Single-centre analysis ofa German transplant centre.Clin Transplant. 2018 Jul;32(7):e13288. doi:10.1111/ctr.13288.

    25. Li J, Koch M, Kramer K, Kloth K, Abu Ganim AR, Scheidat S, Rinninger F, Thaiss F, GulatiA, Herden U, Achilles E, Fischer L,Nashan B. Dual antibody induction and de novo use ofeverolimus enable low-dose tacrolimus with early corticosteroid withdrawal insimultaneous pancreas-kidney transplantation.Transpl Immunol. 2018 Jun 6. pii: S0966- 3274(17)30115-6. doi: 10.1016/j.trim.2018.06.001.

  • more